SCHEMBL29666237

SCHEMBL29666237

CN(CCCNc1nc(Cl)ncc1Br)C(=O)C1CCC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 12/20 0.63
IKBKE Q14164 3/20 0.51
AURKB Q96GD4 2/20 0.51
CDK2 P24941 1/20 0.51
PDPK1 O15530 2/20 0.43
STK17A Q9UEE5 3/20 0.41
MARK4 Q96L34 2/20 0.41
MARK3 P27448 1/20 0.40
STK17B O94768 1/20 0.38
IGF1R P08069 1/20 0.36
VHL P40337 4/20 0.36
ELOC Q15369 4/20 0.36
ELOB Q15370 4/20 0.36
HIF1A Q16665 4/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17162049 1.00 TBK1 (0.63) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL23331357 0.96 TBK1 (0.58) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL21501554 0.94 TBK1 (0.55) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL22818571 0.89 TBK1 (0.51) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL22818563 0.86 TBK1 (0.49) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL22882524 0.86 TBK1 (0.65) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL23330925 0.84 STK17A (0.50) TBK1IKBKEAURKBCDK2STK17A
SCHEMBL22818568 0.82 TBK1 (0.44) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL20201574 0.81 TBK1 (0.79) TBK1IKBKEAURKBCDK2PDPK1
SCHEMBL1284852 0.81 TBK1 (0.61) TBK1IKBKEAURKBCDK2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114262321-A Bistable light-regulated small-molecule protein degradation agent, preparation method and application 中国药科大学 2022-04-01 CN claimed
EP-4649963-A2 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-11-19 EP disclosed
CN-119591582-A Imide-based proteolytic modulators and related methods of use 阿尔维纳斯运营股份有限公司 2025-03-11 CN disclosed
US-20240299366-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2024-09-12 US disclosed
CN-114262321-B Bistable light-regulated small molecular protein degradation agent, preparation method and application 中国药科大学 2024-08-09 CN disclosed
CN-110612294-B Human cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-01-16 CN disclosed
CN-115974840-A Human cereblon ligand and bifunctional compound comprising same 阿尔维纳斯运营股份有限公司 2023-04-18 CN disclosed
CN-114262321-A Bistable light-regulated small-molecule protein degradation agent, preparation method and application 中国药科大学 2022-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299366-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE CRBN, MDM2, UBE2N TBK1 962/4885IKBKE 213/4885AURKB 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.